Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine.

ABSTRACT:

Background

Ukraine remains a high World Health Organization priority country for drug-resistant tuberculosis (TB). Rifampicin-resistant TB (RR-TB) has a more protracted, more complicated, and more expensive treatment. In 2021, Ukraine reported 4025 RR-TB cases - 5.4 times more (751) than all 30 European Union/ European Economic Area countries together.

Objectives

The objective of the study was to determine the diagnostic accuracy of line probe assay (LPA), AID Autoimmun Diagnostika GmbH, for detecting resistance to anti-TB drugs and its clinical application for selecting treatment regimens.

Design

A prospective observational cohort study.

Methods

From May 2019 to June 2020, we consecutively enrolled patients with active TB hospitalized at the Regional Phthisiop

SUBMITTER: Dudnyk A 

PROVIDER: S-EPMC11143817 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature